Targeted Oncology5 小时
Nivolumab-Chemotherapy Combo Boosts PFS in cHL, Poised for Standard Use
The N-AVD regimen showed improved progression-free survival and lower toxicity than BV-AVD in advanced Hodgkin lymphoma, ...
Targeted Oncology21 小时
SELECT Trial Outcomes Support Lenvatinib as RAI-Refractory DTC Therapy
During a Case-Based Roundtable® event, Lori J. Wirth, discussed the SELECT trial and the role of multikinase inhibitors in ...